文献速递妇科生殖医学

宫颈癌保留生育功能治疗后复发风险因素分析:FERTIlity Sparing Surgery 回顾性多中心研究

Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study.
PubMed 文献 · Am J Obstet Gynecol · 2022-11-23

这项回顾性多中心研究纳入13个国家44家机构的733例接受保留生育功能治疗的宫颈癌患者(18-40岁,FIGO 2018 IA1伴淋巴血管间隙浸润阳性或≥IA2),中位随访72个月,复发51例(7%),死亡19例(2.6%)。肿瘤>2 cm者复发风险是≤2 cm者的约3倍(19.4% vs 5.7%;HR 2.982;95%CI 1.383-6.431;P=.005);肿瘤≤2 cm者中根治性与非根治性宫颈手术的复发风险无显著差异(P=.957)。

要点

  • 肿瘤>2 cm者复发风险显著高于≤2 cm者(19.4% vs 5.7%;HR 2.982;P=.005)。
  • 肿瘤≤2 cm者非根治性与根治性宫颈手术复发风险无显著差异(P=.957)。
  • 复发部位以宫颈(53%)和盆腔淋巴结(22%)最常见。

核心结论

  • 在肿瘤≤2 cm的患者中,非根治性保留生育功能宫颈手术与根治性手术相比未增加复发风险。
  • 任何类型保留生育功能手术后,肿瘤>2 cm者的复发风险显著高于≤2 cm者。

研究设计与样本

  • 回顾性观察性多中心研究,纳入18-40岁、FIGO 2018 IA1伴淋巴血管间隙浸润阳性或≥IA2宫颈癌、接受任何类型保留生育功能手术的患者,不限组织学类型、肿瘤分级和新辅助化疗史。
  • 共纳入13个国家44家机构的733例患者。

主要发现

  • 中位随访72个月,51例(7%)复发,其中19例(2.6%)死于该病。
  • 复发部位最常见为宫颈(53%)和盆腔淋巴结(22%)。
  • 肿瘤>2 cm者复发风险是≤2 cm者的约3倍(19.4% vs 5.7%;HR 2.982;95%CI 1.383-6.431;P=.005),与治疗根治性无关。
  • 肿瘤≤2 cm者中,根治性宫颈切除术与非根治性宫颈手术(宫颈锥切和简单宫颈切除术)的复发风险无显著差异(P=.957),无论肿瘤大小亚组(<1 cm或1-2 cm)或淋巴血管间隙浸润状态。

临床怎么用

  • 对于肿瘤≤2 cm的宫颈癌患者,非根治性保留生育功能宫颈手术未显示增加复发风险。
  • 对于肿瘤>2 cm的患者,任何类型保留生育功能手术后复发风险显著升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fertility-sparing treatment in patients with cervical cancer should, in principle, follow identical algorithms to that in patients without future reproductive plans. In recent years, a trend toward nonradical procedures, such as conization or simple trachelectomy, has become apparent in medical literature, because of their associations with better pregnancy outcomes. However, the published reports included small numbers of patients and heterogenous treatment strategies to ascertain the safety of such approaches. OBJECTIVE: This study aimed to collect multi-institutional data regarding the oncological outcomes after fertility-sparing treatment in patients with cervical cancer and to identify prognostic risk factors, including the influence of the radicality of individual cervical procedures. STUDY DESIGN: Patients aged 18 to 40 years with International Federation of Gynecology and Obstetrics 2018 stage IA1 with positive lymphovascular space invasion or ≥IA2 cervical cancer who underwent any type of fertility-sparing procedure were eligible for this retrospective observational study, regardless of their histotype, tumor grade, and history of neoadjuvant chemotherapy. Associations between disease- and treatment-related characteristics with the risk of recurrence were analyzed. RESULTS: A total of 733 patients from 44 institutions across 13 countries were included in this study. Almost half of the patients had stage IB1 cervical cancer (49%), and two-thirds of patients were nulliparous (66%). After a median follow-up of 72 months, 51 patients (7%) experienced recurrence, of whom 19 (2.6%) died because of the disease. The most common sites of recurrence were the cervix (53%) and pelvic nodes (22%). The risk of recurrence was 3 times higher in patients with tumors >2 cm in size than in patients with smaller tumors, irrespective of the treatment radicality (19.4% vs 5.7%; hazard ratio, 2.982; 95% confidence interval, 1.383-6.431; P=.005). The recurrence risk in patients with tumors ≤2 cm in size did not differ between patients who underwent radical trachelectomy and patients who underwent nonradical (conization and simple trachelectomy) cervical procedures (P=.957), regardless of tumor size subcategory (<1 or 1-2 cm) or lymphovascular space invasion. CONCLUSION: Nonradical fertility-sparing cervical procedures were not associated with an increased risk of recurrence compared with radical procedures in patients with tumors ≤2 cm in size in this large, multicenter retrospective study. The risk of recurrence after any type of fertility-sparing procedure was significantly greater in patients with tumors >2 cm in size.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Slama J, Runnebaum IB, Scambia G, et al. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study. Am J Obstet Gynecol. 2022. PMID: 36427596. doi:10.1016/j.ajog.2022.11.1295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。